HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gallucci, V. Articles by Thiene, G. Search for Related Content PubMed PubMed Citation Articles by Gallucci, V. Articles by Thiene, G.

The Annals of Thoracic Surgery, Vol 38, 571-578, Copyright © 1984 by The Society of Thoracic Surgeons

ARTICLES

Isolated mitral valve replacement with the Hancock bioprosthesis: a 13- year appraisal

V Gallucci, U Bortolotti, A Milano, C Valfre, A Mazzucco and G Thiene

Four hundred seventy-six patients underwent isolated mitral valve replacement (MVR) with the glutaraldehyde-preserved porcine Hancock bioprosthesis from March, 1970, through December, 1981. There were 312 female and 164 male patients ranging in age at operation from 9 to 68 years (average, 53 years). Associated surgical procedures were performed in 35 patients. Hospital mortality was 13%, the main cause of death being low-output syndrome. The survivors were followed from 1.6 to 13.2 years (mean, 5.2 years). Cumulative duration of follow-up is 2,180 patient-years and is 97% complete. Overall late mortality is 3.1 +/- 0.3% per patient-year, and actuarial survival is 73.8 +/- 3.4% at 13 years. Embolic accidents occurred in 45 patients and were fatal in 13; the linearized incidence of postoperative systemic thromboemboli is 2.1 +/- 0.3% per patient-year. Reoperation was necessary in 49 patients: in 4 because of valve endocarditis, with 3 deaths; in 6 because of perivalvular leak, with no deaths; in 2 because of left atrial thrombosis; and in 37 because of valve dysfunction due to primary tissue failure, caused mainly by calcific degeneration of the tissue, with 5 operative deaths. Actuarial freedom from primary tissue failure is 58 +/- 6.6% at 13 years. Extended follow-up after MVR with the Hancock bioprosthesis confirms the satisfactory performance and low thrombogenicity of this device up to 13 years after operation.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				T. Bottio, M. Valente, G. Rizzoli, V. Tarzia, G. Bisleri, E. Pettenazzo, G. Gerosa, and G. Thiene Commissural dehiscence: a rare and peculiar cause of porcine valve structural deterioration. J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1017 - 1022. [Abstract] [Full Text] [PDF]

				T. Gudbjartsson, S. Aranki, and L. H. Cohn Mechanical/Bioprosthetic Mitral Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 951 - 986. [Full Text]

				G. Stellin, M. Padalino, O. Milanesi, V. Vida, A. Favaro, M. Rubino, R. Biffanti, and D. Casarotto Repair of congenital mitral valve dysplasia in infants and children: is it always possible? Eur. J. Cardiothorac. Surg., July 1, 2000; 18(1): 74 - 82. [Abstract] [Full Text] [PDF]

				U. Bortolotti, A. Milano, G. Thiene, and A. Mazzucco Original expectations of the Hancock valve and 20 years of clinical reality Eur. J. Cardiothorac. Surg., January 1, 1992; 6(suppl_1): S75 - S78. [Abstract] [PDF]